The mutant KRAS results in immune evasion by recruiting myeloid-derived suppressor cell (MDSC) and impairing CD8+ T cell activity via inhibition of IRF2 and activation of CXCL3 production in mouse models with colorectal tumors (26). This evidence concerns the gene KRAS and colorectal neoplasm.